Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

China Medical Technologies prostrate cancer diagnostic test

China Medical Technologies : 04 April, 2008  (New Product)
China Medical Technologies has developed the Prostate Cancer FISH Detection Kit, a prostate cancer-specific molecular diagnostic test based on the Fluorescent in situ Hybridisation technology.
The company expects to launch the kit in July 2008.

The kit is designed to detect TMPRSS2 and ETS gene fusions in prostate pathological tissues. Dysregulation of ETS family members through fusions with TMPRSS2 are implicated as cancer-causing gene rearrangements in prostate cancer, which can aid in the detection of early prostate cancer. The Kit consists of three dual-colour probe sets, namely TMPRSS2/ETV1 probes, TMPRSS2/ERG probes and TMPRSS2/ETV4 probes.

Studies have shown that TMPRSS2/ETS gene fusions occur in approximately 80 percent of prostate cancer cases, indicating that the application of TMPRSS2/ETS gene fusions as specific biomarkers can significantly increase the sensitivity for prostate cancer diagnosis. In addition, it has been reported that the TMPRSS2/ERG fusion may have prognostic significance.

'The successful development of the Kit is a milestone in expanding our FISH reagent portfolio, which represents the first significant product developed by our researchers since the FISH acquisition in 2007,' said Xiaodong Wu, chairman and chief executive officer of the company. 'Our FISH business has become an important growth driver of the Company and we believe the continual launch of new FISH reagents with huge potential of diagnostic application will drive the growth of our recurring reagent business rapidly.'

Prostate cancer is one of the most frequent cancers among men in China and many other countries. In China, prostate-related diseases affect about 60 to 70 percent of men over 60 years of age of which the population is about 80 million. Among them, patients with prostate enlargement who need surgical therapy have the opportunity to benefit from the use of the kit to resolve the diagnosis of prostate cancer.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo